Skip to main content
SpringerLink
Log in

Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs

  • Regulatory Science
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

Abstract

For any medicinal product Marketing Authorization Application (MAA) in the European Union, the applicant needs to indicate the legal basis for the application. This legal basis, laid down in Directive 2001/83/EC as amended, determines the dossier content, the market exclusivity, and the pediatric requirements in a significant way. For new development projects for established active substances, including new strengths, dosage forms, routes of administration, and new indications, the correct choice of legal basis is critical. This article presents the dossier requirements, data protection, and market exclusivity as well as pediatric obligations for mixed MAAs using the Article 8(3) legal basis and so-called “hybrid” applications according to Article 10(3). These legal bases in the European Union are contrasted with applications according to section 505(b)(2) in the United States. A number of case studies are presented to illustrate which factors can determine the legal basis of an MAA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended. https://doi.org/ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf.

  2. Committee for Medicinal Products for Human Use (CPMP). Guideline on the Non-clinical Documentation for Mixed Marketing Authorisation Applications. London: European Medicines Agency; 2005. CPMP/SWP/799/95.

    Google Scholar 

  3. Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004. https://doi.org/ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf.

  4. Regulation (EC) No. 1902/2006 of the European Parliament and of the Council of 20 December 2006 amending 1901/2006 on medicinal products for paediatric use. https://doi.org/ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1902/reg_2006_1902_en.pdf.

  5. European Medicines Agency. Decision P/345/2010. London: European Medicines Agency; 2010.

    Google Scholar 

  6. European Medicines Agency, Decision of 8 September 2008 on a class waiver on a class of medicinal products in accordance with Regulation (EC) No. 1901/2006 of the European Parliament and of the Council as amended. https://doi.org/www.ema.europa.eu/docs/en_GB/document_library/Other/2009/11/WC500011743.pdf.

  7. Committee for Medicinal Products for Human Use (CHMP). Investigation of Bioequivalence. London: European Medicines Agency; 2010. CPMP/EWP/QWP/1401/98 Rev. 1.

    Google Scholar 

  8. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. https://doi.org/ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141/reg_2000_141_en.pdf.

  9. Federal Food, Drug, and Cosmetic (FD&C) Act, §505(b)(2). https://doi.org/www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/default.htm.

  10. Center for Drug Evaluation and Research (CDER), Guidance for Industry: Applications Covered by Section 505(b)(2). Washington, DC: US Food and Drug Administration; 1999. Draft

    Google Scholar 

  11. European Medicines Agency. PecFent European Public Assessment Report. London: European Medicines Agency; 2011.

    Google Scholar 

  12. European Medicines Agency. Controloc Control European Public Assessment Report. London: European Medicines Agency; 2011

    Google Scholar 

  13. European Medicines Agency. Pedea European Public Assessment Report. London: European Medicines Agency; 2009

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoires CTRS, 69 rue d’Aguesseau, 92100, Boulogne-Billancourt, France

    Andreas M. Vogel PhD

Authors
  1. Andreas M. Vogel PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas M. Vogel PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogel, A.M. Hybrid or Mixed Marketing Authorization Application in the European Union: Not a Trivial Decision in New Development Programs for Established Drugs. Ther Innov Regul Sci 46, 479–484 (2012). https://doi.org/10.1177/0092861512443748

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/0092861512443748

Keywords

Search

Navigation